Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
189,947,836
-
Total 13F shares
-
44,505,507
-
Share change
-
+601,604
-
Total reported value
-
$89,003,268
-
Put/Call ratio
-
0%
-
Price per share
-
$2.00
-
Number of holders
-
75
-
Value change
-
-$637,458
-
Number of buys
-
25
-
Number of sells
-
46
Institutional Holders of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) as of Q1 2022
As of 31 Mar 2022,
Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) was held by
75 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,505,507 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., M28 Capital Management LP, MAVERICK CAPITAL LTD, Bellevue Group AG, PRIMECAP MANAGEMENT CO/CA/, Kynam Capital Management, LP, PLATINUM INVESTMENT MANAGEMENT LTD, D. E. Shaw & Co., Inc., Ikarian Capital, LLC, and Artal Group S.A..
This page lists
75
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.